Biotech investor, banker and analyst personnel changes

Biren Amin has left as biotechnology and healthcare sector analyst at WJB Capital to join Jefferies as a senior research analyst. As a result, WJB has dropped coverage of drug delivery company Alkermes Inc. (NASDAQ:ALKS); neurology and autoimmune company Elan Corp. plc (NYSE:ELN); pulmonary company InterMune Inc. (NASDAQ:ITMN); specialty pharma Questcor Pharmaceuticals Inc. (NASDAQ:QCOR); and genitourinary company Vivus Inc. (NASDAQ:VVUS).

Michael King returned to the banking world, joining Rodman & Renshaw as managing director and senior biotechnology analyst. He was most recently SVP of corporate development and communication at Ziopharm Oncology Inc. (NASDAQ:ZIOP)...